Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

Summary

This phase II trial studies how well nivolumab works in treating patients with stage IV lung cancer or that has come back after initial treatment who has high mutation loads. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.

Timeline

Start

2017-12-29

Primary completion

2019-07-30

Completion

2020-07-30

Outcome

Outcome not reported

Stopped: “Research cancelled”

Drugs

Indications